Virios Therapeutics granted Nasdaq exception until Oct 28, 2024 to regain $1.00 bid price compliance

Dogwood Therapeutics, Inc.

Nasdaq Hearing Panel grants exception until October 28, 2024 to meet minimum $1.00 bid price rule.
If not compliant by October 11, 2024, Company must pursue a reverse stock split by the deadline.
Failure to regain compliance by October 28, 2024 will result in delisting from Nasdaq Capital Market.
Initial deficiency notice was received November 7, 2023; prior 180-day cure period expired April 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.